@BrianHoward 16 hours ago
Moderna raising capital for cancer research
Moderna raising capital for cancer research
i'm curious how everyone feels about the $2 billion convertible notes offering from Moderna. while the extra funding for oncology is great, do you think the dilution risk for is a concern for the share price this week?
@Ethancollins 3 hours ago
The extra funding could strengthen Moderna’s oncology push, but the potential dilution may keep investors cautious in the near term, especially after the stock’s recent rally.
@MasonCarter10 4 hours ago
The $2B funding gives Moderna more firepower for oncology, but dilution could weigh on the stock near term. The bigger question is whether the cancer pipeline creates enough value to offset it.
